Impact of glucagon‐like peptide‐1 receptor agonists on the incidence of inflammatory bowel disease in people with type 2 diabetes
Authors' conclusion
Among patients with T2DM, GLP-1 RA users demonstrated a significantly lower risk of developing IBD than basal insulin and DPP-4i users. GLP-1 RA users also showed a lower risk of hospitalisation. GLP-1 RAs may contribute to lowering the risk of IBD in individuals with T2DM.
Study context
- Population
- Patients with T2D, TriNetX US collaborative network, 1 January 2014 to 31 December 2022matched cohorts
- Participants
- 3,165,521 patients
- Exposure
- GLP-1 RA vs basal insulin, DPP-4i and SGLT2i
- Outcome
- Development of inflammatory bowel disease (IBD)
Methodological detailspropensity-score matched, TriNetX US collaborative network
- Propensity-score matched
- TriNetX US collaborative network
Main finding
As reported in the abstract
IBD
Hazard ratio (95% CI)
GLP-1 RAvs Basal insulin
0.725(0.564–0.931)
GLP-1 RAvs DPP-4i
0.814(0.686–0.966)
Observational data: associations, not effects.
Further findings
| Outcome | HR (95% CI) | |
|---|---|---|
| HospitalisationGLP-1 RAvs Basal insulin | 0.144 (0.140–0.148) | |
| HospitalisationGLP-1 RAvs DPP-4i | 0.660 (0.647–0.672) | |
| HospitalisationGLP-1 RAvs SGLT2i | 0.792 (0.775–0.809) | |
| 0.10.31310Hazard ratio (log scale) |
Original publication
Impact of glucagon‐like peptide‐1 receptor agonists on the incidence of inflammatory bowel disease in people with type 2 diabetes. Diabetes Obes Metab. Published 27 August 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →